Castleman's disease associated with amyloidosis. Literature review and clinical observation

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

A brief review of the literature on Castleman's disease (CD), a rare heterogeneous group of lymphoproliferative diseases of unknown etiology with characteristic lymph node histopathology, is presented. Depending on the clinical, pathological, virological features and course, the modern classification of CD includes a unicentric variant (UCD) with a localized lesion of a single lymph node, a generalized or multicentric variant (MCD) with lymphadenopathy in several nodes, and an intermediate variant – oligocentric, or regional, affecting lymph nodes in two – three neighboring areas. Differential diagnosis of CD requires mandatory testing for infection with the herpes virus (HHV8) and human immunodeficiency virus, as well as the exclusion of all concomitant diseases, since CD can be accompanied by the development of Hodgkin's lymphoma and non-Hodgkin's lymphomas, Kaposi's sarcoma, which has important prognostic and therapeutic value. Amyloidosis AA (AA-A) is caused by a wide range of inflammatory conditions but is rarely associated with CD.

Description of the clinical case. We report a clinical case of a 29-year-old woman with idiopathic multicentric plasma cell variant of CD, complicated by AA amyloidosis with kidney and lymph node damage, restrictive cardiomyopathy, and dialysis-requiring end-stage renal failure.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Nadiya Frolova

City Clinical Hospital № 52 of the Moscow Healthcare Department; A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Хат алмасуға жауапты Автор.
Email: nadiya.frolova@yandex.ru
ORCID iD: 0000-0003-3234-8266

Cand. Sci. (Med.), Deputy Chief Physician for Nephrological Care, City Clinical Hospital №52 of the Moscow Healthcare Department

Ресей, Moscow; Moscow

Valery Varyasin

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: pao52@mail.ru
ORCID iD: 0000-0003-1136-6203

Cand.Sci. (Med.), Head of the Pathological Anatomical Department, City Clinical Hospital №52 of the Moscow Healthcare Department

Ресей, Moscow

Galina Volgina

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: volginagv@mail.ru
ORCID iD: 0000-0002-7771-4074

Dr. Sci. (Med.), Professor, A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Ресей, Moscow

Irina Sysoeva

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: i.l.sysoeva@mail.ru
ORCID iD: 0000-0002-1904-9846

Doctor at the Nephrology Department, City Clinical Hospital №52 of the Moscow Healthcare Department

Ресей, Moscow

Rinat Mudarisov

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: docmr@rambler.ru
ORCID iD: 0000-0001-8890-4669

Cand. Sci. (Med.), Deputy Chief Physician for Surgical Care, City Clinical Hospital №52 of the Moscow Healthcare Department

Ресей, Moscow

Sergey Usatyuk

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: usatuk-doc@mail.ru
ORCID iD: 0000-0002-8742-3860

Head of the Nephrology Department, City Clinical Hospital №52 of the Moscow Healthcare Department

Ресей, Moscow

Ekaterina Dyakova

City Clinical Hospital № 52 of the Healthcare Department

Email: katerina-diakova@mail.ru
ORCID iD: 0000-0003-1599-1639

Doctor at the Nephrology Department, City Clinical Hospital №52 of the Moscow Healthcare Department

Ресей, Moscow

Ekaterina Stolyarevich

City Clinical Hospital № 52 of the Moscow Healthcare Department; A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: Stolyarevich@yandex.ru
ORCID iD: 0000-0002-0402-8348

Dr. Sci. (Med.), Professor at the Department of Nephrology, FAPE, A.I. Yevdokimov Moscow State University of Medicine and Dentistry; Pathologist at the Department of Pathological Anatomy, City Clinical Hospital №52 of the Moscow Healthcare Department

Ресей, Moscow; Moscow

Әдебиет тізімі

  1. Castleman B., Towne V.W. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N. Engl. J. Med. 1954;251(10):396–400. doi: 10.1056/NEJM195409022511008.
  2. Castleman B., Iverson I., Menendez V.P. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9(4):822–30. doi: 10.1002/1097-0142(195607/08)9:4<822:aid-cncr2820090430>3.0.co;2-4.
  3. Fajgenbaum D.C., Uldrick T.S., Bagg A., et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–57. Doi: 10.1182/ blood-2016-10-746933.
  4. Dispenzier A., Fajgenbaum D.C. Overview of Castleman disease. Blood. 2020;135(16):1353–64. doi: 10.1182/blood.2019000931.
  5. Iwaki N., Fajgenbaum D.C., Nabel C.S., et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am. J. Hematol. 2016;91(2):220–6. doi: 10.1002/ajh.24242.
  6. Wang W., Medeiros L.J. Castleman Disease. Surg. Pathol. Clin. 2019;12(3):849–63. doi: 10.1016/j.path.2019.03.003.
  7. Rekhtina I., Stolyarevich E., Zakharova V., et al. A case of POEMS syndrome with severe kidney damage: lessons for the clinical nephrologist. J. Nephrol. 2022;35(8):2135–8. doi: 10.1007/s40620-022-01379-w. [Epub 2022 Jun 23].
  8. Rhee F., Oksenhendler E., Srkalovic G., et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020;4(23):6039–50. doi: 10.1182/bloodadvances.2020003334.
  9. Al-Amri A.M., Abdul-Rahman I.S., Ghallab K.Q. Castleman’s disease: a study of a rare lymphoproliferative disorder in a university hospital. Gulf. J. Oncolog. 2010;7:25–36. doi: 10.4137/cmbd.s2161.
  10. Меликян А.Л., Егорова Е.К., Ковригина А.М. и др. Клинико-морфологические особенности различных вариантов болезни Кастельмана. Тер. архив. 2015;87(7):64–71. doi: 10.17116/terarkh201587764-71. [Melikyan A.L., Egorova E.K., Kovrigina A.M., et al. Kliniko-morfologicheskie osobennosti razlichnykh variantov bolezni Kastel'mana. Ther. Arch. 2015;87(7):64–71 (In Russ.)].
  11. Егорова Е.К., Ковригина А.М., Меликян А.Л. Морфологические и иммуногистохимические особенности различных вариантов болезни Кастлемана Часть 1. Диагностические критерии смешанно-клеточного варианта. Клиническая и экспериментальная морфология. 2017;1(21):16–23. [Egorova E.K., Kovrigina A.M., Melikyan A.L. Morphological and immunohistochemical features of various variants of Castleman's disease Part 1. Diagnostic criteria of the mixed-cell variant. Clin. Exp. Morphol. 2017;1(21):16–23 (In Russ.)].
  12. Cohen A. B., Swaminathan А., Xiaoliang Wang Х., et al. Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease. J. Clin. Oncol. 2021;39:7048–48. doi: 10.1200/JCO.2021.39.15_suppl.7048.
  13. Simpson D. Epidemiology of Castleman disease. Hematol. Oncol. Clin. North. Am. 2018;32:1–10.
  14. Carbone А., Borok М., Damania B., et al. Castleman disease. Nat. Rev. Dis. Primers. 2021;7(1):84. doi: 10.1038/s41572-021-00317-7.
  15. Zhang L., Li Z., Cao X., et al. Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman’s disease: renal function is an important prognostic factor. Sci. Rep. 2016;6:23831. doi: 10.1038/srep23831. [PMID: 27029894; PMCID: PMC4814900].
  16. alat N., Belgaumkar A.P., Schulte K.M. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann. Surg. 2012;255(4):677–84. doi: 10.1097/SLA.0b013e318249dcdc.
  17. Simpson D. Epidemiology of Castleman disease. Hematol. Oncol. Clin. North. Am. 2018;32(1):1–10. doi: 10.1016/j.hoc.2017.09.001.
  18. Gonçalves P.H., Uldrick T.S., Yarchoan R. HIV-associated Kaposi sarcoma and related diseases. AIDS. 2017;31:1903–16. doi: 10.1097/QAD.0000000000001567.
  19. Cesarman E., Damania В., Krown S.E., et al. Kaposi sarcoma. Nat. Rev. Dis. Primers. 2019;5:9. doi: 10.1038/s41572-019-0060-9.
  20. Oksenhendler E., Boutboul D., Fajgenbaum D., et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br. J. Haematol. 2018;180(2):206–16. doi: 10.1111/bjh.15019.
  21. Zhang M.Y., Jia M.-N., Chen J. et al. UCD with MCD-like inflammatory state: surgical excision is highly effective. Blood Adv. 2021; 5(1): 122–128. doi: 10.1182/bloodadvances.2020003607.
  22. outboul D., Fadlallah J., Chawki S., et al. Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases. Br. J. Haematol. 2019;186(2):269–73. doi: 10.1111/bjh.15921.
  23. Ramaswami R., Lurain К., Polizzotto M.N., et al. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. Blood Adv. 2021;5(6):1660–70. doi: 10.1182/bloodadvances.2020004058.
  24. Fajgenbaum D.C. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018;132:2323–30. https://doi.org/10.1182/blood-2018-05-848671
  25. Zhou Т., Wang H-W., Pittaluga S., Jaffe E.S. Multicentric Castleman disease and the evolution of the concept. Pathologica. 2021;113(5):339–53. doi: 10.32074/1591-951X-351.
  26. Liu A.Y., Nabel C.S., Finkelman B.S., et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet. Hematol. 2016;3(4):e163–75. doi: 10.1016/s2352-3026(16)00006-5.
  27. Kang D., Lee J., Lee H., Baek S. Unicentric Castleman’s disease in the orbit: a case report. Indian J. Ophthalmol. 2015;63(6):555–57. Doi: 10.4103/ 0301-4738.162645.
  28. He X., Wang Q., Wu Y., et al. Comprehensive analysis of 225 Castleman’s diseases in the oral maxillofacial and neck region: a rare disease revisited. Clin. Oral Investig. 2018;22(3):1285–95. doi: 10.1007/s00784-017-2232-x.
  29. Akram W., Degliuomini J., Wallack M.K., et al. Unicentric Castleman’s disease masquerading as a carcinoid tumor of the small intestine. Am. Surg. 2016;82(9):e287–89. [PMID: 27670551].
  30. Eward W.C., DeWitt S.B., Brigman B.E., et al. Extranodal Castleman disease of the extremities: a case report and review of the literature. Skeletal Radiol. 2014;43:1627–31. doi: 10.1007/s00256-014-145-z.
  31. Kazakov D.V., Fanburg-Smith J.C., Suster S., et al. Castleman disease of the Subcutis and underlying skeletal muscle. Report of cases. Am. J. Surg. Pathol. 2004;28(5):569–77. doi: 10.1097/00000478-200405000-00002.
  32. Васильев В.И., Пальшина С.Г., Павловская А.И. и др. Идиопатическая мультицентрическая болезнь Кастлемана. Тер. архив. 2020;92(5):78–84. doi: 10.26442/00403660.2020.05.000440. [Vasilyev V.I., Palshina S.G., Pavlovskaya A.I., et al. Idiopathic multicentric Castleman's disease. Ther. Arch. 2020;92(5):78–84].
  33. Zhao О., Zhang Х., Yang Х., Huang S. Castleman's disease in the pelvic retroperitoneum: A case report. Exp. Ther. Med. 2022;24(5):660. doi: 10.3892/etm.2022.11596.
  34. Dispenzieri A. POEMS syndrome: 2019 up-date on diagnosis, risk-stratification, and management. Am. J. Hematol. 2019;94(7):812–27.
  35. Dupin N., Diss T.L., Kellam P., et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95(4):1406–12. PMID: 10666218.
  36. Carbone A., De Paoli P., Gloghini A., Vaccher, E. KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. Int. J. Cancer 2015;137:251–61.
  37. Masaki Y., Nakajima A., Iwao H., et al. Japanese variant of multicentric Castleman’s disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J. Clin. Exp. Hematop. 2013;53(1):79–85. https://doi.org/10.3960/jslrt.53.57
  38. Fujimoto S., Sakai T., Kawabata H., et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am. J. Hematol. 2019;94:975–83. https://doi. org/10.1002/ajh.25554
  39. Sakashita K., Murata K., Takamori M. TAFRO syndrome: current perspectives. J. Blood Med. 2018;9:15–23. https://doi.org/10.2147/ JBM.S127822
  40. Yu L., Tu M., Cortes J., et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017;129:1658–68. [Epub 2017 Jan 18]. https://doi.org/10.1182/ blood-2016-11-748855
  41. van Rhee F., Voorhees P., Dispenzieri A., et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132:2115–24. https://doi.org/10.1182/blood-2018-07-862334
  42. Yuan X.G., Hu W., Chen F.F., et al. Renal complications of Castleman's disease: report of two cases and analysis of 75 cases. Clin. Exp. Nephrol. 2011;15(6):921–6. doi: 10.1007/s10157-011-0499-9.
  43. un P.P., Yu X.J., Wang S.X., et al. Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease. Nephrol. (Carlton). 2020;25(2):125–34. doi: 10.1111/nep.13630.
  44. Noda Y., Saka Y., Kato A., et al. Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage. Clin. Nephrol. Case Stud. 2018;6:16–20. doi: 10.5414/CNCS109400.
  45. Mutneja A., Cossey L.N., Liapis H., Chen Y.M. A rare case of renal thrombotic microangiopathy associated with Castleman's disease. BMC. Nephrol. 2017;18(1):57. doi: 10.1186/s12882-017-0472-2.
  46. Saito H., Tanaka K., Fujiwara M., et al. Castleman's disease, glomerulonephritis Pathological findings of progressive renal involvement in a patient with TAFRO syndrome. Cen. Case Rep. 2019;8(4):239–45. Doi: 10.1007/ s13730-019-00400-9.
  47. Leurs A., Gnemmi V., Lionet A., et al. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. Front. Immunol. 2019;10:1489. doi: 10.3389/fimmu.2019.01489.
  48. Furuto Y., Hashimoto H., Horiuti H., Shibuya Y. Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor: A case report. Medicine (Baltimore). 2018;97(24):e11057. doi: 10.1097/MD.0000000000011057.
  49. Kurose N., Mizutani K., Kumagai M.. et al. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Pathol. Res. Pract. 2019;215(3):410–13. Doi: 10.1016/j.
  50. Xu D., Lv J., Dong Y., et al. Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol. Dial. Transplant. 2012;27(Suppl. 3):iii119–25. doi: 10.1093/ndt/gfr245.
  51. Morishita N.Y., Oh I., Saito O., et al. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab). Intern. Med. 2012;51(11):1375–78.
  52. Zoshima T., Yamada K., Hara S., et al. Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports. Am. J. Surg. Pathol. 2016;40(4):495–501. doi: 10.1097/PAS.0000000000000575.
  53. Hsu H.H., Chen Y.C., Fang J.T., et al. Unicentric Castleman's disease associated with hydronephrosis. Urol. 2000;56(5):856. doi: 10.1016/s0090-4295(00)00783-4.
  54. Kim Y.S., Jung M.H. Retroperitoneal Castleman's disease presenting with hydronephrosis indistinguishable from lymphoma. J. Obstet. Gynaecol. Res. 2011;37(8):1145–48. doi: 10.1111/j.1447-0756.2010.01488.x.
  55. Lee T.H., Kim W., Jeong Y.B., et al. Haematuria and hydronephrosis caused by Castleman's disease. NDT. Plus. 2009;2(6):502–3. doi: 10.1093/ndtplus/sfp105.
  56. Li Y., Zhao H., Su B., et al. Primary hyaline vascular Castleman disease of the kidney: case report and literature review. Diagn. Pathol. 2019;14:94. doi: 10.1186/s13000-019-0870-9.
  57. Ooi C.C., Cheah F.K., Wong S.K. Castleman's disease of the kidney: Sonographic findings. J. Clin. Ultrasound. 2015;43(7):438–42. doi: 10.1002/jcu.22192.
  58. Koh Y., Kinjo T., Nonomura D., Yamamoto Y., et al. Castleman's disease of the kidney: a case report. Hinyokika Kiyo. 2014;60(3):129–32. [PMID: 24759499].
  59. Ивановская М.И., Стаценко Е.А., Кушнеров А.И. др. Два случая болезни Кастлемана в Онкоурологической практике. Военная медицина. 2010;2(15):133–5.
  60. Bernabei L., Waxman A., Caponetti G., et al. AA amyloidosis associated with Castleman disease: a case report and review of the literature. Medicine. 2020;99:6(e18978). http://dx.doi.org/10.1097/MD.0000000000018978
  61. Fayand A., Boutboul D., Galicier L., et al. Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review. Amyloid. 2019;26(4):197–202. doi: 10.1080/13506129.2019.1641078.
  62. Yamada Y., Ueno T., Irifuku T., et al. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report. Clin. Nephrol. 2018;90(3):232–36. doi: 10.5414/CN109273.
  63. Paydas S., Paydas S., Ergin M. Colchicine therapy in amyloidosis related with plasmacytic Castleman disease presenting with nephrotic syndrome. Saudi J. Kidney Dis. Transpl. 2015;26(5):992–95. doi: 10.4103/1319-2442.164589.
  64. van der Hilst J.C.H., Yamada T., Op den Camp H.J.M., et al. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatol. 2008;47: 1651–54.
  65. Obici L., Raimondi S., Lavatelli F., et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthr. Rheum. 2009;61:1435–40.
  66. Захарова Е.В. Редкие варианты системного амилоидоза. Обзор литературы и клинические наблюдения. Нефрология и диализ. 2013;3:221–31. [Zakharova E.V. Rare variants of systemic amyloidosis. Literature review and clinical observations. Nephrol. Dial. 2013;3:221–31].
  67. Altiparmak M.R., Pamuk G.E., Pamuk O.N., et al. Secondary amyloidosis in Castleman’s disease: review of literature and report of a case. Ann. Hematol. 2002;81(6):336–39. doi: 10.1007/s00277-002-0444-9.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Classification of Castleman's disease

Жүктеу (86KB)
Метадеректер
3. Fig. 2. Kidney biopsy

Жүктеу (267KB)
Метадеректер
4. Fig. 3. Computed tomography of the abdominal organs, enlarged lymph nodes and formation in the hilum of the spleen

Жүктеу (82KB)
Метадеректер
5. Fig. 4. Macropreparation of the formation in the hilum of the spleen 4 cm in diameter, a dense homogeneous structure in the section with small lymph nodes adjacent to it with a diameter of up to 0.7 cm

Жүктеу (265KB)
Метадеректер
6. Fig. 5. Lymphoid follicles with an expanded mantle. Staining with hematoxylin and eosin x50

Жүктеу (289KB)
Метадеректер
7. Fig. 6. Layers of plasma cells in the paracortical zone. Staining with hematoxylin and eosin x200

Жүктеу (211KB)
Метадеректер
8. Fig. 7. Deposition of eosinophilic masses. Histochemical staining Congo red x50

Жүктеу (228KB)
Метадеректер
9. Fig. 8. Immunohistochemistry. Expression of IgG4 x400

Жүктеу (189KB)
Метадеректер
10. Fig. 9. Immunohistochemistry. Expression of IgG x400

Жүктеу (209KB)
Метадеректер
11. Fig. 10. Immunohistochemistry. Expression of Lambda x200 light chains

Жүктеу (184KB)
Метадеректер
12. Fig. 11. Immunohistochemistry. Expression of Kappa x200 light chains

Жүктеу (182KB)
Метадеректер

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>